Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 0.84 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.84 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.77 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.77 |
| ▸ | LMNA | P02545 | 3/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.77 |
| ▸ | USP2 | O75604 | 2/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.77 |
| ▸ | TSHR | P16473 | 2/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.77 |
| ▸ | MEN1 | O00255 | 1/20 | 0.77 |
| ▸ | BRAF | P15056 | 1/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.77 |
| ▸ | LCK | P06239 | 3/20 | 0.70 |
| ▸ | KDR | P35968 | 2/20 | 0.69 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3339302 | 0.91 | MAPT (1.00) | EGFRMAPTGRM1ERBB2CLK4 | |
| Hydrochloric Acid SCHEMBL29624330 | 0.90 | MAPT (0.97) | EGFRMAPTGRM1ERBB2CLK4 | |
| Hydrochloric Acid SCHEMBL7417527 | 0.90 | MAPT (0.97) | EGFRMAPTGRM1ERBB2CLK4 | |
| SCHEMBL15052375 | 0.89 | BRAF (0.82) | EGFRMAPTGRM1ERBB2CLK4 | |
| SCHEMBL25465024 | 0.89 | EGFR (1.00) | EGFRMAPTGRM1ERBB2CLK4 | |
| SCHEMBL1387244 | 0.88 | EGFR (1.00) | EGFRMAPTGRM1ERBB2CLK4 | |
| SCHEMBL15052369 | 0.87 | CLK4 (1.00) | EGFRMAPTGRM1CLK4LMNA | |
| Hydrochloric Acid SCHEMBL8808379 | 0.87 | EGFR (0.98) | EGFRMAPTGRM1ERBB2CLK4 | |
| SCHEMBL2101550 | 0.87 | EGFR (0.76) | EGFRMAPTGRM1ERBB2CLK4 | |
| SCHEMBL2100465 | 0.86 | MAPT (0.84) | EGFRMAPTGRM1ERBB2BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180099946-A1 | Quinazoline Derivatives as VEGF Inhibitors | GENZYME CORPORATION (US) | 2018-04-12 | — | — | US | disclosed |
| US-20160130249-A1 | Quinazoline Derivatives as VEGF Inhibitors | ASTRAZENECA AB (SE) | 2016-05-12 | — | — | US | disclosed |
| US-9040548-B2 | Quinazoline derivatives as VEGF inhibitors | ASTRAZENECA AB (SE) | 2015-05-26 | — | — | US | disclosed |
| US-20140121228-A1 | Quinazoline Derivatives as VEGF Inhibitors | ASTRAZENECA AB (SE) | 2014-05-01 | — | — | US | disclosed |
| US-8642608-B2 | Quinazoline derivatives as VEGF inhibitors | ASTRAZENECA AB (SE) | 2014-02-04 | — | — | US | disclosed |
| US-8349857-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2013-01-08 | — | — | US | disclosed |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20110065736-A1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | ASTRAZENECA AB (SE) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099946-A1 | Quinazoline Derivatives as VEGF Inhibitors | FLT4, FLT1, KDR | EGFR 199/4885MAPT 4622/4885GRM1 2913/4885 |
| US-20110065736-A1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | FLT1, FLT4, KDR | EGFR 183/4885MAPT 4682/4885GRM1 3062/4885 |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | ERBB2, EGFR, ABL1 | EGFR 2/4885MAPT 4100/4885GRM1 713/4885 |
| US-20160130249-A1 | Quinazoline Derivatives as VEGF Inhibitors | FLT1, FLT4, KDR | EGFR 181/4885MAPT 4667/4885GRM1 3087/4885 |
| US-20140121228-A1 | Quinazoline Derivatives as VEGF Inhibitors | FLT4, FLT1, KDR | EGFR 120/4885MAPT 4060/4885GRM1 2475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.